SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001213900-20-003723
Filing Date
2020-02-14
Accepted
2020-02-14 06:11:11
Documents
1
Group Members
PONTIFAX CAYMAN III L.P.PONTIFAX MANAGEMENT FUND III L.P.PONTIFAX MANAGEMENT III G.P. (2011) LTD.PONTIFAXISRAEL III L.P.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 3 TO SCHEDULE 13G sc13g0220a3pontifax_enlivex.htm SC 13G/A 110259
  Complete submission text file 0001213900-20-003723.txt   111954
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Subject) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-88278 | Film No.: 20613555
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O KITE PHARMA, INC. 2225 COLORADO AVENUE SANTA MONICA CA 90404
Business Address
Nussbaum Ran (Filed by) CIK: 0001609805 (see all company filings)

Type: SC 13G/A